CMS Expands Patient-Centered Innovation with Substance Access BEI

Centers for Medicare & Medicaid Services (CMS) has introduced the Substance Access Beneficiary Engagement Incentive (BEI)

The Centers for Medicare & Medicaid Services (CMS) has introduced the Substance Access Beneficiary Engagement Incentive (BEI), a new initiative aimed at advancing patient-centered care through innovative treatment options.

A key feature of this model is the inclusion of hemp-derived products. With CMS approval, participating organizations may provide eligible beneficiaries up to $500 per year in hemp-derived products—subject to clinical determination, model requirements, and safeguards.

To qualify, products must comply with the 2018 Agriculture Improvement Act and contain

no more than 0.3% delta-9 THC. The model excludes inhalable products, items with more than 3 mg of THC per serving, and any cannabinoids not naturally produced by the cannabis plant. Importantly, the initiative does not override the Controlled Substances Act or authorize Schedule I substances.

All eligible products must meet strict federal, state, and local requirements, including third-party testing for potency and contaminants, ensuring safety and quality.

This milestone reflects CMS’s commitment to expanding safe, compliant, and patient-focused care options while maintaining strong regulatory oversight.

For more details, read the full CMS announcement: https://www.cms.gov/newsroom/press-releases/cms-marks-milestone-expanding-patient-centered-innovation-substance-access-beneficiary-engagement

---

Do you have questions about federal or state-level regulations and laws related to land use, hemp, psilocybin, or other agricultural products?

Our expert team is happy to assist.

Please email us at info@earthlawllc.com or give us a call at 541-632-3946.